Want to see RGEN full AI Analyst Report?
RGEN Stock Chart & Stats
$131.96
-$5.64(-4.10%)
At close: 4:00 PM EDT
$131.96
-$5.64(-4.10%)
Day’s Range― - ―
52-Week Range$100.99 - $175.77
Previous CloseN/A
Volume1.36M
Average Volume (3M)1.14M
Market Cap
$8.10B
Enterprise Value$7.61K
Total Cash (Recent Filing)$810.45M
Total Debt (Recent Filing)$690.94M
Price to Earnings (P/E)190.6
Beta1.04
Next Earnings
Nov 03, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding56,435,620
10 Day Avg. Volume1,377,252
30 Day Avg. Volume1,139,495
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$169.92Price Target Upside28.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)2.06
Revenue Forecast (FY)$827.39M
Bulls Say, Bears Say
Bulls Say
Cash GenerationRepligen’s trailing‑twelve‑month operating and free cash flow strength provides durable internal funding for R&D, bolt‑on M&A, and share‑holder optionality. Strong cash conversion cushions the business against cyclical revenue swings and underpins multi‑year investments and the transformation program.
Margin Recovery & ProfitabilityMargins have meaningfully improved versus 2024 with notable Q1 expansion, reflecting better product mix and cost leverage. Sustained mid‑single digit to low‑double digit operating margins support cash flow durability and improve resilience to episodic revenue lumpiness over the next 2–6 months.
Strategic M&A Expands Cell Therapy ExposureAcquiring BioLife materially broadens Repligen’s exposure to cell therapy and biopreservation, adding products used in many commercial cell therapies. If executed, accretive revenue, cross‑sell opportunities and near‑term synergies can sustainably diversify end markets and raise long‑term growth runway.
Bears Say
Revenue & Margin VolatilityHistorical cyclicality and a return to profitability from a loss year highlight uneven demand sensitivity across biologics programs. Continued volatility reduces predictability of earnings and ROE, making it harder to rely on steady cash returns or to plan long‑lead capex investments over the next several quarters.
Execution & Integration RiskExpanding in China via OEM arrangements and integrating BioLife both create multi‑year execution burdens. Local competition and delayed partner ramp increase the risk that expected synergies and market share gains materialize slower, pressuring revenue and margin improvement timelines through 2027.
Capital Equipment & Timing DependenceA meaningful portion of systems revenue depends on customer facility readiness and capex cycles, which are episodic. Lumpy equipment orders make near‑term revenue timing uncertain, complicate capacity planning, and can cause quarter‑to‑quarter swings in absorption‑driven margins over the next several reporting periods.
Repligen News
RGEN FAQ
What was Repligen’s price range in the past 12 months?
Repligen lowest stock price was $100.99 and its highest was $175.77 in the past 12 months.
What is Repligen’s market cap?
Repligen’s market cap is $8.10B.
When is Repligen’s upcoming earnings report date?
Repligen’s upcoming earnings report date is Nov 03, 2026 which is in 94 days.
How were Repligen’s earnings last quarter?
Repligen released its earnings results on Jul 28, 2026. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.447 by $0.093.
Is Repligen overvalued?
According to Wall Street analysts Repligen’s price is currently Undervalued.
Does Repligen pay dividends?
Repligen does not currently pay dividends.
What is Repligen’s EPS estimate?
Repligen’s EPS estimate is 0.46.
How many shares outstanding does Repligen have?
Repligen has 56,435,620 shares outstanding.
What happened to Repligen’s price movement after its last earnings report?
Repligen reported an EPS of $0.54 in its last earnings report, beating expectations of $0.447. Following the earnings report the stock price went up 10.896%.
Which hedge fund is a major shareholder of Repligen?
Currently, no hedge funds are holding shares in RGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$169.92 (28.76% Upside)
$169.92 (28.76% Upside)
Blogger Sentiment
Bullish
RGEN Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.76%
Trailing 12-Months
Company Description
Repligen
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGEN Company Deck
RGEN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: the company reported healthy top-line growth ($194M, +15% reported, +11% organic), notable margin expansion (gross margin +180 bps, operating margin +160 bps), strong franchise performances (Analytics +50%+, Chromatography >25%, Proteins mid-teens), solid cash position ($785M), and raised adjusted EPS guidance. Management launched a transformation office targeting at least 1 point of annualized margin benefit by end of 2027 and announced a strategic OEM partnership in China. Key headwinds are mostly timing and structural: divestiture of a loss-making Polymem reduced revenue (~$7M), ATF/gene therapy customer timing moderated near-term growth (expected to rebound in 2027), some Q1 margin benefits may normalize, and there is execution risk around customer readiness for capital equipment and competition in China. Overall, positives (growth, margins, guidance, strategic initiatives, cash) materially outweigh the manageable lowlights tied to timing, one-off costs, and a small divestiture impact.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$169.92
▲(28.76% Upside)
Technical Analysis
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
0.68% Insiders
42.62% Mutual Funds
9.63% Other Institutional Investors
24.78% Public Companies and
Individual Investors